Stratifying HR+ HER2- breast cancer through ER signaling and G2/M molecular signatures

Molecular signatures improve patient stratification beyond standard IHC clinical markers

INDICATION
Breast
BIOMARKER
ER Signaling

 

Kaplan-Meier survival curves comparing groups of high/low ER signaling activity and high/low G2/M (proliferation) checkpoint activity. Progression as event. No risk set adjustment performed. Median survival times (months) are specified.

 

Related cases

Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Three abstract data distributions displayed as shapes made of small, colored squares.

Sacituzumab govitecan and tumor microenvironment shifts in metastatic triple-negative breast cancer

2026-07-01
CXCL/SPP1 (CS)
Breast
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
A blue grid with dark blue squares forming a descending diagonal path, possibly a heatmap.

Optimizing therapy sequencing for HR+ HER2- metastatic breast cancer

2026-05-26
Breast
HER2
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Unable to determine image content.

ESR1 mutations and copy number loss in breast cancer

2026-05-26
Breast
ESR1